Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome
- 1 January 2014
- journal article
- review article
- Published by Georg Thieme Verlag KG in Thrombosis and Haemostasis
- Vol. 112 (11) , 924-931
Abstract
Summary: Acute coronary syndrome (ACS) is a medical emergency. Patients who survive the initial event remain at risk of recurrent cardiovascular events. In most cases, ACS is triggered by thrombosis after rupture of an atherosclerotic plaque. Key to thrombus formation at this site is the generation of thrombin, which not only converts fibrinogen to fibrin but also serves as a potent platelet agonist and induces platelet aggregation at the site of vascular injury. Although dual antiplatelet therapy is more effective for the prevention of recurrent events than aspirin alone after ACS, there remains an approximately 10 % risk of recurrent ischaemic events at one year. Recent studies have evaluated whether the addition of an anticoagulant to antiplatelet therapy reduces the risk of recurrent ischaemia after an ACS event. Rivaroxaban, an oral factor Xa inhibitor, attenuates thrombin generation. When used in conjunction with dual antiplatelet therapy in patients with stabilised ACS, rivaroxaban 2.5 mg twice daily significantly reduced the risk of the composite endpoint of cardiovascular death, myocardial infarction and stroke compared with placebo. Although it increased the risk of bleeding, rivaroxaban was associated with a reduction in mortality; a finding that supports the use of a dual-pathway approach that combines anticoagulant and antiplatelet therapy. This review explores the pathophysiology of ACS to provide perspective on the results of recent clinical trials with novel oral anticoagulants for ACS and to identify their potential role in this setting.Keywords
Funding Information
- Bayer HealthCare Pharmaceuticals
This publication has 34 references indexed in Scilit:
- Antiplatelet Drug Use in Patients with Non-ST-Segment Elevation Acute Coronary SyndromesPostgraduate Medicine, 2013
- Prasugrel versus Clopidogrel for Acute Coronary Syndromes without RevascularizationNew England Journal of Medicine, 2012
- Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic AttackStroke, 2012
- Ticagrelor versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2009
- Meta-Analysis of the Efficacy and Safety of Clopidogrel Plus Aspirin as Compared to Antiplatelet Monotherapy for the Prevention of Vascular EventsThe American Journal of Cardiology, 2008
- Prasugrel versus Clopidogrel in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2007
- Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and BenefitAnnals of Internal Medicine, 2005
- Coagulation activation and long-term outcome in acute coronary syndromesBlood, 2003
- Acute coronary syndrome: unstable angina and non-ST segment elevation myocardial infarctionBMJ, 2003
- Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)European Heart Journal, 2000